News
Adjuvant Immunotherapy in Early-Stage NSCLC — Roy Herbst leads a discussion with Julie Brahmer and Sarah Goldberg
Adjuvant chemotherapy has been the standard of care for patients with resectable non-small cell lung cancer (NSCLC), but newer therapies are entering the mix as well. At the American Society of Clinical Oncology (ASCO) annual meeting, findings from several trials on the role of adjuvant immunotherapy were presented.
MedPage Today brought together three expert leaders in the field: Moderator Roy Herbst, MD, PhD, of Yale Cancer Center in New Haven, Connecticut, is joined by Julie Brahmer, MD, of Johns Hopkins Sidney Kimmel Comprehensive Cancer Center in Baltimore, and Sarah Goldberg, MD, MPH, also of Yale Cancer Center, for a virtual roundtable discussion. This second of four exclusive episodes focuses on NSCLC treatment in the adjuvant setting.
Source: MedPage Today